Pharmaceuticals

Respiratory Disease Vaccine Market 2026–2030: Forecast, Innovation, and Competitive Trends

February 18, 2026February 24, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the respiratory disease vaccine market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Respiratory Disease Vaccine Market covering 2026–2035?

The respiratory disease vaccine market size has seen modest expansion in recent years. This market is set to increase from $70.03 billion in 2025 to $71.36 billion in 2026, achieving a compound annual growth rate (CAGR) of 1.9%. The historical market expansion can be credited to factors such as the high prevalence of respiratory infections, the constrained availability of effective vaccines, government-led immunization initiatives, breakthroughs in monoclonal antibody research, and heightened awareness concerning respiratory health.

The market size for respiratory disease vaccines is anticipated to show consistent growth over the coming years. This sector is projected to reach $81 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 3.2%. The expansion during the forecast period can be attributed to a rising demand for universal vaccines, advancements in mRNA and viral vector vaccine technologies, an increase in cold-chain infrastructure, growth in public-private partnerships for vaccine distribution, and a strategic focus on pandemic preparedness and rapid response. Significant trends expected in the forecast period include the development of next-generation respiratory vaccines, a heightened emphasis on pediatric and geriatric immunization, the expansion of immunization programs in emerging markets, the emergence of combination vaccines for multi-pathogen protection, and the adoption of rapid vaccine development and distribution platforms.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12924&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Respiratory Disease Vaccine Market?

The increasing incidence of tuberculosis (TB) is anticipated to drive the future expansion of the respiratory disease vaccine market. Tuberculosis, an infectious respiratory illness caused by Mycobacterium tuberculosis, predominantly affects the lungs and represents a considerable worldwide health challenge. The surge in TB cases is attributed to elements such as compromised healthcare systems, delayed diagnoses, and broader transmission patterns, collectively intensifying the disease burden. Respiratory disease vaccines are vital in mitigating TB-related risks by lowering infection rates, constraining transmission, and bolstering global prevention strategies. As an illustration, in March 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, the count of tuberculosis cases rose from 8,320 in 2022 to 9,615 in 2023, marking an increment of 1,295 cases. Hence, the growing prevalence of tuberculosis is stimulating the growth of the respiratory disease vaccine market.

What Segments Are Identified Within The Structure Of The Respiratory Disease Vaccine Market?

The respiratory disease vaccine market covered in this report is segmented –

1) By Type: Viral Vaccine, Bacterial Vaccine, Combination Vaccine

2) By Infection: COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Other Infections

3) By Age: Infant, Adolescent, Adult

4) By End-User: Clinic, Hospital, Other End-Users

Subsegments:

1) By Viral Vaccine: Influenza Vaccine, Respiratory Syncytial Virus (RSV) Vaccine, Coronavirus Vaccine

2) By Bacterial Vaccine: Pneumococcal Vaccine, Haemophilus Influenzae Type B (Hib) Vaccine, Pertussis Vaccine

3) By Combination Vaccine: DTaP With Hib And IPV, Pneumococcal Conjugate Vaccine With Influenza Vaccine

What Trends Are Expected To Impact The Competitive Landscape Of The Respiratory Disease Vaccine Market?

Leading firms within the respiratory disease vaccine sector are focusing their efforts on developing novel products aimed at boosting their effectiveness and offering superior options for averting and managing respiratory disease infections. As an example, in May 2023, Pfizer Inc., a pharmaceutical company based in the US, secured Food and Drug Administration (FDA) approval for its ABRYSVO (Respiratory Syncytial Virus Vaccine). This bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine is intended for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in individuals 60 years of age and older. ABRYSVO is an unadjuvanted vaccine, composed of two preF proteins specifically designed to optimize immunity against both RSV A and B varieties, and has demonstrated clinical safety and effectiveness.

Which Key Market Players Are Investing In Expansion And Innovation Within The Respiratory Disease Vaccine Market?

Major companies operating in the respiratory disease vaccine market are Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Sinovac Biotech Co. Ltd., Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Emergent BioSolutions Inc., Seqirus, Bio Farma, Dynavax Technologies Corporation, Hualan Biological Bacterin Co. Ltd., Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Valneva SE, Biological E. Limited, CanSino Biologics Inc., Bharat Biotech International Limited, Medicago Inc, CureVac N.V., Incepta Vaccine Ltd, Inovio Pharmaceuticals Inc., Ology Bioservices, VBI Vaccines Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report

Which Regions Are Poised For Strategic Growth In The Respiratory Disease Vaccine Market?

Asia-Pacific was the largest region in the respiratory disease vaccine market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory disease vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Respiratory Disease Vaccine Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12924&type=smp

Browse Through More Reports Similar to the Global Respiratory Disease Vaccine Market 2026, By The Business Research Company

Respiratory Disease Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Influenza Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795